Moderna Inc. has announced the submission of an application to the U.S. Food and Drug Administration (FDA) for the review of its Spikevax 2025-2026 COVID-19 vaccine formula. This new vaccine targets the SARS-CoV-2 variant LP.8.1, following FDA guidance that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant. The review by the FDA is ongoing, and Moderna is awaiting potential approval in the U.S. This regulatory submission highlights Moderna's continued efforts in advancing mRNA technology to address emerging variants of the virus. There is no indication in the announcement that this submission involves funding or grants obtained by multiple organizations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。